rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GRAL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri Gains ...

      GRAIL Inc (GRAL) eyes early 2027 FDA approval for Galleri after a favorable advisory committee vote, even as revenue growth slows and losses widen.

      Nov 10Yahoo FinanceGRAL
      GRAIL (GRAL) Q3 2026 Earnings Call Transcript

      Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.

      Nov 5The Globe and MailGRAL
      GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
      Nov 5Yahoo FinanceGRAL
      Why is Grail stock tumbling today?
      Nov 5Investing.comGRAL
      What GRAIL (GRAL) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceGRAL
      Grail tumbles as revenue misses estimates despite FDA vote
      Nov 4Investing.comGRAL
      Grail earnings on deck as FDA approval for cancer test looms
      Nov 4Investing.comGRAL
      GRAIL, Inc. (GRAL) Surged After FDA Panel Backed Its Cancer Detection Test: Here’s Why
      Nov 3Yahoo FinanceGRAL
      How Long Can GRAIL Keep Burning Cash?
      Nov 3Yahoo FinanceGRAL
      GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
      Oct 29Yahoo FinanceGRAL
      Grail CEO Joshua Ofman sells $2.74m in company stock
      Oct 17Investing.comGRAL
      TD Cowen Adjusts GRAIL Price Target to $188 From $88, Maintains Buy Rating

      GRAIL (GRAL) has an average rating of overweight and mean price target of $134.30, according to anal

      Oct 13Yahoo FinanceGRAL
      TD Cowen raises Grail stock price target to $180 on FDA outlook
      Oct 13Investing.comGRAL
      Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
      Oct 11Yahoo FinanceGRAL
      Jim Cramer Breaks Down the Stakes in Detail as GRAIL (GRAL) Awaits Its Next Big Decision
      Oct 10Yahoo FinanceGRAL
      Grail Insider Sold Shares Worth $3,457,585, According to a Recent SEC Filing
      Oct 8Yahoo FinanceGRAL
      Grail CFO Aaron Freidin sells $3.46m in company stock
      Oct 8Investing.comGRAL
      Grail chief growth officer Andrew Partridge sells $1.15m in stock
      Oct 8Investing.comGRAL
      Why CVS Is ‘Insanely Cheap,’ ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
      Oct 7Yahoo FinanceGRALCVS
      Grail Inc stock hits all-time high at 151.48 USD
      Oct 5Investing.comGRAL
      Grail to present cancer detection data at medical conferences
      Oct 5Investing.comGRAL
      Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
      Oct 5Yahoo FinanceGRAL
      Grail Jumps as Cancer Test Nears Market
      Oct 5Yahoo FinanceGRAL
      Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)
      Oct 4Yahoo FinanceGRALMRNA
      Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results
      Oct 2Yahoo FinanceGRAL
      A Cancer Test Has Investors Betting Big. But Will Insurers Pay?
      Oct 1WSJGRAL
      Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

      Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailGRAL
      GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL)
      Sep 28Seeking AlphaGRAL
      Grail stock price target raised to $150 by Canaccord on FDA outlook
      Sep 28Investing.comGRAL
      Grail CFO Aaron Freidin sells $382,679 in company stock
      Sep 27Investing.comGRAL
      Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21
      Sep 27Investing.comGRAL
      Mizuho raises Grail stock price target to $100 on FDA panel vote
      Sep 25Investing.comGRAL
      Here's Why Grail Stock Surged 55% This Week

      The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri.

      Sep 25Yahoo FinanceGRAL
      Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

      Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.

      Sep 25The Globe and MailGRAL
      GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued?
      Sep 24Yahoo FinanceGRAL
      FDA Panel Endorses GRAIL Galleri Cancer Screening Tool - GRAIL (NASDAQ:GRAL)

      The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.

      Sep 24BenzingaGRAL
      One blood test could screen you for 50 cancers. Here’s why it’s controversial.

      A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works. The test is awaiting a final decision by the FDA.

      Sep 24The Washington PostGRAL
      Grail stock hits all-time high at 119.09 USD
      Sep 24Investing.comGRAL
      Canaccord reiterates Buy on Grail stock after FDA panel vote
      Sep 24Investing.comGRAL
      What is next for Grail stock after surging on positive FDA comments?
      Sep 24Investing.comGRAL
      Why is Grail stock surging today?
      Sep 24Investing.comGRAL
      RBC Capital Sticks to Their Hold Rating for GRAIL Inc (GRAL)

      Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailGRAL
      Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

      Detailed price information for Grail Inc (GRAL-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailGRAL
      Grail’s cancer-screen blood test wins tepid support from US drug advisory panel
      Sep 23Financial TimesGRAL
      FDA panel endorses first-of-a-kind cancer blood test from Grail
      Sep 23AP NewsGRAL
      US FDA advisers endorse Grail cancer test's benefits in key vote
      Sep 23ReutersGRAL
      Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
      Sep 23WSJGRAL
      F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
      Sep 23The New York TimesGRAL
      The Holy Grail In Cancer? FDA Panel Backs Blood Tests.

      An FDA panel discussed the company's blood screening test for cancer.

      Sep 23Investor's Business DailyGRAL
      Grail’s Blood Test to Detect Multiple Cancers Wins FDA Panel Backing
      Sep 23BloombergGRAL

      This is the newest page. Registered accounts read further back.